Creative Biolabs boosts biotherapeutics research by combining specialized immunology assays with advanced microfluidics to help researchers profile immune responses and build flexible, fit‑for‑purpose workflows.

Rapid action involving sophisticated market participants raises a broader question: Who is monitoring unusual trading activity when public companies and retail shareholders may be harmed?

Creative Biolabs, a premier global CRO, today announced the expansion of its preclinical development pipeline specifically engineered for complex LBPs.

Creative Biotherapeutics, LLC, led by Anita Davidson, DPT, and Dr. Don Davidson, is advancing CBT300, an investigational biologic therapeutic candidate targeting drug resistance, immune evasion, recurrence, and metastasis in cancer treatment failure.

Creative Biolabs is leading the way in developing next-generation probiotics by assisting in the development of engineered strains with novel methods in gut microbiota research.

Creative Biolabs develops services for drug discovery using B. bifidum probiotics, which encompass strain design and genetic engineering.